Ergoteles’s Humacyte HUMA Stock Holding History

Ergoteles’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-74,392	Closed	-$157K	–	1470
2022 Q4	$157K	Buy	74,392 +43,116	+138%	+$131K	0.01%	1133
2022 Q3	$102K	Buy	+31,276	New	+$120K	﹤0.01%	1373

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ergoteles's HUMA Position: Q1 2023 in Review

Ergoteles sold out of Humacyte (HUMA) in Q1 2023, closing a stake of 74,392 shares — an estimated $157K sold.

Ergoteles first reported a position in HUMA in Q3 2022 and held it in 2 quarters. The position peaked at $157K in Q4 2022. 69 funds tracked by Wall St. Rank hold HUMA as of Q1 2023.

Ergoteles reported no remaining Humacyte position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 74,392 Humacyte shares in Q1 2023, an estimated $157K.
Ergoteles first reported a position in Humacyte in Q3 2022 and held it in 2 quarters.
Ergoteles's Humacyte position peaked at $157K in Q4 2022.
69 funds tracked by Wall St. Rank held Humacyte as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.